These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18923820)

  • 41. Effects of chronic social defeat on behavioral and neural correlates of sociality: Vasopressin, oxytocin and the vasopressinergic V1b receptor.
    Litvin Y; Murakami G; Pfaff DW
    Physiol Behav; 2011 Jun; 103(3-4):393-403. PubMed ID: 21397619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oxytocin and vasopressin in the medial amygdala differentially modulate approach and avoidance behavior toward illness-related social odor.
    Arakawa H; Arakawa K; Deak T
    Neuroscience; 2010 Dec; 171(4):1141-51. PubMed ID: 20933576
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of peripheral vasopressin 1A and oxytocin receptors on the subcutaneous vasopressin antinociceptive effects.
    Manzano-García A; González-Hernández A; Tello-García IA; Martínez-Lorenzana G; Condés-Lara M
    Eur J Pain; 2018 Mar; 22(3):511-526. PubMed ID: 29082571
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants.
    Nicolas LB; Kolb Y; Prinssen EP
    Eur J Pharmacol; 2006 Oct; 547(1-3):106-15. PubMed ID: 16934246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure.
    Mondritzki T; Mai TA; Vogel J; Pook E; Wasnaire P; Schmeck C; Hüser J; Dinh W; Truebel H; Kolkhof P
    Eur J Heart Fail; 2021 May; 23(5):743-750. PubMed ID: 32946151
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide (SCH 655842): comparison of efficacy and side effects across rodent species.
    Lu SX; Higgins GA; Hodgson RA; Hyde LA; Del Vecchio RA; Guthrie DH; Kazdoba T; McCool MF; Morgan CA; Bercovici A; Ho GD; Tulshian D; Parker EM; Hunter JC; Varty GB
    Eur J Pharmacol; 2011 Jul; 661(1-3):63-71. PubMed ID: 21545797
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of vasopressin V1b receptor antagonist, SSR149415, on anxiety-like behavior and Lewis lung carcinoma metastasis in mice.
    Amikishieva AV; Ilnitskaya SI; Nikolin VP; Popova NA
    Exp Oncol; 2011 Sep; 33(3):126-9. PubMed ID: 21956463
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity.
    Méchaly I; Laurent F; Portet K; Serrano J; Cros G
    Eur J Pharmacol; 1999 Nov; 383(3):287-90. PubMed ID: 10594321
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species.
    Varty GB; Hyde LA; Hodgson RA; Lu SX; McCool MF; Kazdoba TM; Del Vecchio RA; Guthrie DH; Pond AJ; Grzelak ME; Xu X; Korfmacher WA; Tulshian D; Parker EM; Higgins GA
    Psychopharmacology (Berl); 2005 Oct; 182(1):132-43. PubMed ID: 16025321
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spinal vasopressin alleviates formalin-induced nociception by enhancing GABAA receptor function in mice.
    Peng F; Qu ZW; Qiu CY; Liao M; Hu WP
    Neurosci Lett; 2015 Apr; 593():61-5. PubMed ID: 25782631
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selective and non-selective OT receptor agonists induce different locomotor behaviors in male rats via central OT receptors and peripheral V1a receptors.
    Wolfe M; Wisniewska H; Tariga H; Ibanez G; Collins JC; Wisniewski K; Qi S; Srinivasan K; Hargrove D; Lindstrom BF
    Neuropeptides; 2018 Aug; 70():64-75. PubMed ID: 29807652
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of arginine vasopressin on human anxiety and associations with sex, dose, and V1a-receptor genotype.
    Thompson RR; Price D; Burris D; Cloutier A; Rilling JK
    Psychopharmacology (Berl); 2024 Jun; 241(6):1177-1190. PubMed ID: 38358527
    [TBL] [Abstract][Full Text] [Related]  

  • 53. WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action.
    Hicks C; Ramos L; Reekie TA; Narlawar R; Kassiou M; McGregor IS
    Psychopharmacology (Berl); 2015 Aug; 232(15):2659-67. PubMed ID: 25761839
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of small molecule vasopressin V1a and V2 receptor antagonists on brain edema formation and secondary brain damage following traumatic brain injury in mice.
    Krieg SM; Sonanini S; Plesnila N; Trabold R
    J Neurotrauma; 2015 Feb; 32(4):221-7. PubMed ID: 25111427
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New topics in vasopressin receptors and approach to novel drugs: involvement of vasopressin V1a and V1b receptors in nociceptive responses and morphine-induced effects.
    Honda K; Takano Y
    J Pharmacol Sci; 2009 Jan; 109(1):38-43. PubMed ID: 19151540
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.
    Serradeil-Le Gal C; Wagnon J; Garcia C; Lacour C; Guiraudou P; Christophe B; Villanova G; Nisato D; Maffrand JP; Le Fur G
    J Clin Invest; 1993 Jul; 92(1):224-31. PubMed ID: 8392086
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anxiolytic-like effects of alverine citrate in experimental mouse models of anxiety.
    Gupta D; Radhakrishnan M; Kurhe Y
    Eur J Pharmacol; 2014 Nov; 742():94-101. PubMed ID: 25199966
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Septal vasopressin modulates anxiety-related behaviour in rats.
    Liebsch G; Wotjak CT; Landgraf R; Engelmann M
    Neurosci Lett; 1996 Oct; 217(2-3):101-4. PubMed ID: 8916082
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A new linear V1A vasopressin antagonist and its use in characterizing receptor/G protein interactions.
    Strakova Z; Kumar A; Watson AJ; Soloff MS
    Mol Pharmacol; 1997 Feb; 51(2):217-24. PubMed ID: 9203626
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist.
    Ring RH; Schechter LE; Leonard SK; Dwyer JM; Platt BJ; Graf R; Grauer S; Pulicicchio C; Resnick L; Rahman Z; Sukoff Rizzo SJ; Luo B; Beyer CE; Logue SF; Marquis KL; Hughes ZA; Rosenzweig-Lipson S
    Neuropharmacology; 2010 Jan; 58(1):69-77. PubMed ID: 19615387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.